



PTO/SB/08B (10-01)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

10

Complete if Known

Application Number	09/664,444
Filing Date	September 18, 2000
First Named Inventor	John C. Bell
Group Art Unit	1645
Examiner Name	Robert A. Zeman
Attorney Docket Number	18003

+

NON PATENT PUBLICATIONS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
RZ		Kim, et al., "Replicating Viruses as Selective Cancer Therapeutics", Molecular Medicine Today, pages 519-527, December 1996.	
		Heise, et al., "Onyx-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytosis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents", Nature Medicine, Vol 3, No. 6, pages 639-645, June 1997.	
		Zhang, et al. "Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy", Proc. Natl. Acad. Sci. USA, Vol 93, pages 4513-4518, April 1996.	
		Katze, "Regulation of the interferon-induced PKR: can viruses cope?", Trends in Microbiology, Vol. 3, No. 2, pages 75-78, February 1995.	
		Maheshwari, et al., "Low Infectivity of Vesicular Stomatitis Virus (VSV) Particles Released from Interferon-Treated cells is Related to Glycoprotein Deficiency", Biochemical and Biophysical Research Communications, Vol. 117, No 1, pages 161-168, November 30, 1983.	
		Chou, et al., "Association of a Mr 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhancing phosphorylation of translationsimplex virus 1", Proc. Natl. Acad. Sci. USA, Vol 92, pages 10516-10520, November 1995.	
		Xu, et al., "Primary Leukemia Cells Resistant to x-Interferon in Vitro are Defective in the Activation of the DNA-Binding Factor Interferon-Stimulated Gene Factor 3", Blood, Vol. 84, No. 6, pages 1942-1949, September 1994.	
		Petricoin III, et al., "Human Cancer Cell Lines Express a Negative Transcriptional Regulator of the Interferon Regulatory Factor Family of DNA Binding Proteins", Molecular and Cellular Biology, Vol. 14, No. 2, pages 1477-1486, February 1994.	
		Symons, et al., "Vaccinia Virus Encodes a Soluble Type I Interferon Receptor of Novel Structure and Broad Species Specificity", Cell, Vol. 81, Pages 551-560, May 19, 1995.	
		Linge, et al., "Interferon System Defects in Human Malignant Melanoma", Cancer Research, Vol. 55, pages 4099-4104, September 15, 1995.	
RZ		Machida, et al. "Effective of Nucleosides on Interferon Production and Development of Antiviral State Induced by Poly I-Poly C", Microbiolo. Immunol., Vol. 23 (7), pages 643-650, 1979	


Examiner Signature	<i>Robert A. Zeman</i>	Date Considered	5/17/04
--------------------	------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 10

Complete if Known

Application Number	09/664,444
Filing Date	September 18, 2000
First Named Inventor	John C. Bell
Group Art Unit	1645
Examiner Name	Robert A. Zeman
Attorney Docket Number	18003

NON PATENT PUBLICATIONS


Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RZ		Tanaka, et al., "Cellular Commitment to Oncogene-Induced Transformation or Apoptosis is Dependent on the Transcription Factor IRF-1", Cell, Vol. 77, pages 829-839, June 17, 1994.	
		Pennisi, "Will a Twist of Viral Fate Lead to a New Cancer Treatment?", Science, Vol. 274, Pages 342-343, October 18, 1996.	
		Bischoff, et al., "An Adenovirus Mutant that Replicates Selectively in p53-Deficient Human Tumor Cells", Science, Vol. 274, pages 373-376, October 18, 1996.	
		Andreansky, et al., "The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors", Proc. Natl. Acad. Sci. USA, Vol. 93, pages 11313-11318, October 1996. Colloquium Paper	
		Gastl, et al., "Retroviral Vector-mediated Lymphokine Gene Transfer into Human Renal Cancer Cells", Cancer Research, 52, pages 6229-6236, November 1992.	
		Buller, et al., "Cell Proliferative Response to Vaccinia Virus Is Mediated by VGF", Virology, Vol. 164, pages 182-192. 1988.	
		Child, et al., "Insertional Inactivation of the Large Subunit of Ribonucleotide Reductase Encoded by Vaccinia Virus Is Associated with Reduced Virulence in Vivo", Virology, Vol. 174, pages 625-629, 1990.	
		Restifo, et al., "A Nonimmunogenic Sarcoma Transduced with the cDNA for Interferon (Elicits CD8+ T Cells against the Wild-type Tumor...Presentation Capability", The Journal of Experimental Medicine, Vol. 175, pages 1423-1431, June 1992.	
		Buller, et al., "Decreased Virulence of Recombinant Vaccinia Virus Expression Vectors is Associated with a Thymidine Kinase-Negative Phenotype", Nature, Vol. 317, pages 813-815, October 31, 1985	
		Haines, et al., "Correlation of the expression of double-stranded RNA-dependent protein kinase (p68) with differentiation in head and neck squamous cell carcinoma", Virchows Archiv B Cell Pathology, Vol. 63, pages 289-295, 1993	
RZ		James, et al., "Chromosome 9 Deletion Mapping Reveals Interferon α and Interferon B-1 Gene Deletions in Human Glial Tumors", Cancer Research, Vol 51, pages 1684-1688, March 15, 1991.	

Examiner Signature	<i>Robert A. Zeman</i>	Date Considered	5/17/04
--------------------	------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

10

Complete if Known

Application Number	09/664,444
Filing Date	September 18, 2000
First Named Inventor	John C. Bell
Group Art Unit	1645
Examiner Name	Robert A. Zeman
Attorney Docket Number	18003

NON PATENT PUBLICATIONS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
RZ		Arroyo, et al., "Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon x in a murine hepatic metastasis model", Cancer Immunology Immunotherapy, Vol. 31, pages 305-311, 1990.	
		Zhang, et al., "High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus", Cancer Gene Therapy, Vol. 1, No. 1, pages 5-13, 1994.	
		Korth, et al., "Cloning, expression, and cellular localization of the oncogenic 58-kDa inhibitor of the RNA-activated human and mouse protein kinase", Gene, Vol. 170, pages 181-188, 1996.	
		Barber, et al., "The 58-kilodalton inhibitor of the interferon-induced double-stranded RNA-activated protein kinases is tetratricopeptide repeat protein with oncogenic properties", Proc. Natl. Acad. Sci. USA, Vol. 91, pages 4278-4282, May 1994.	
		Matthews, et al., "Adenovirus Virus-Associated RNA and Translation Control", Journal of Virology, Vol. 65, No. 11, pages 5657-5662, Nov. 1991.	
		Imani, et al., "Inhibitory activity for the interferon-induced protein kinase is associated with the reovirus serotype...protein", Proc. Natl. Acad. Sci. USA, Vol. 85, pages 7887-7891, November 1988.	
		Tanaka, et al., "Immunotherapy of Vaccinia Colon Oncolysate Prepared with Interleukin-2 Gene-Encoded Vaccinia Virus and Interferon-x Increase the Survival of Mice Bearing Syngeneic Colon Adenocarcinoma", Journal of Immunotherapy, Vol. 16, No. 4, Pages 283-293, 1994.	
		Csatary, et al., "Attenuated Veterinary Virus Vaccine for the Treatment of Cancer", Cancer Detection and Prevention, Vol 17, No. 6, pages 619-627, 1993.	
		Cassel, et al., "Newcastle Disease Virus as an Antineoplastic Agent", Cancer, Vol. 18, No. 7, pages 863-868, July 1965.	
		Schirrmacher, et al. "Successful application of non-oncogenic viruses for antimetastatic cancer immunotherapy", Institut für Immunologie und Genetik am Deutschen Krebsforschungszentrum, 6900 Heidelberg, Germany, pages 19-49, March 13, 1986.	
RZ		Lorenz, et al., "Newcastle Disease Virus as an Antineoplastic Agent: Induction of Tumor Necrosis Factor- x and Augmentation of Its Cytotoxicity", Journal of the National Cancer Institute, Vol. 80, No. 16, pages 1305-1312, October 19, 1988.	

Examiner Signature

Robert A. Zeman

Date Considered

5/12/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Information contained herein is not a legal document unless it contains a valid QMID.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	09/664,444
		Filing Date	September 18, 2000
		First Named Inventor	John C. Bell
		Group Art Unit	1645
		Examiner Name	Robert A. Zeman
Sheet	4	of	10
		Attorney Docket Number	

NON PATENT PUBLICATIONS


Examiner Initials'	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>RZ</i>		Reichard, et al., "Newcastle Disease Virus Selectively Kills Human Tumor Cells", Journal of Surgical Research, Vol 52, pages 448-453, 1992.	
		Eaton, et al., "Contribution of Antiviral Immunity to Oncolysis by Newcastle Disease Virus in a Murine Lymphoma", Journal of the National Cancer Institute, Vol. 39, No. 6, December 1967.	
		Beverley, et al., "Immune Responses in Mice to Tumor Challenge After Immunization with Newcastle Disease Virus-Infected or X-Irradiated Tumor Cells or Cell Fractions", Int. Journal of Cancer, Vol. 11, pages 212-223, 1973.	
		Shoham, et al., "Augmentation of Tumor Cell Immunogenicity by Viruses - An Approach to Specific Immunotherapy of Cancer", Nat. Immun. Cell Growth Regul., Vol. 9, pages 165-172, 1990.	
		Bart, et al., "Role of Interferon in the Anti-Melanoma Effects of Poly(I).Poly(C) and Newcastle Disease Virus", Nature New Biology, Vol. 245, No. 147, pages 229-230, October 24, 1973.	
		Sinkovics, et al., "New Developments in the Virus Therapy of Cancer: A Historical Review", Intervirology, Vol. 36, pages 193-214, 1993.	
		Murray, et al., "Viral Oncolytic in the Management of Malignant Melanoma", Cancer, Vol. 40, No. 2, pages 680-686, August 1977.	
		Cassel, "A Phase II Study on the Postsurgical Management of Stage Malignant Melanoma with a Newcastle Disease Virus Oncolytic", Cancer, Vol. 52, pages 856-860, September 1, 1983.	
		Cassel, "A Ten-Year Follow-Up on Stage II Malignant Melanoma Patients Treated Postsurgically with Newcastle Disease Virus Oncolytic", Med. Oncol. & Tumor Pharmacother., Vol. 9, No. 4, pages 169-171, 1992.	
		Bohle, et al. "Postoperative Active Specific Immunization in Colorectal Cancer Patients with Virus-Modified Autologous Tumor-Cell Vaccine", Cancer, Vol. 66, No. 7, pages 1517-1523, October 1, 1990.	
		<i>RZ</i> Eaton, et al., "Autoimmunity Induced by Injection of Virus-Modified Cell Membrane Antigens in Syngeneic Mice", Infection and Immunity, Vol. 15, No. 1, pages 322-328, January 1977.	

Examiner Signature		Date Considered	5/17/04
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 10

Complete If Known

Application Number	09/664,444
Filing Date	September 18, 2000
First Named Inventor	John C. Bell
Group Art Unit	1645
Examiner Name	Robert A. Zeman

Attorney Docket Number 18003

NON PATENT PUBLICATIONS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published.	T ²
RZ		Wheelock, et al, "Observation on the Repeated Administration of Viruses to a Patient with Acute Leukemia", The New England Journal of Medicine, Vol. 271, No. 13, pages 645-651, September 24, 1964.	
		Csاتر, "Viruses in the Treatment of Cancer", The Lancet, page 825, October 9, 1971.	
		Kenney, et al., "Viruses as Oncolytic Agents: A New Age for "Therapeutic" Viruses?", JNCL Editorial Issue 16, pages 1-3, June 20, 1997.	
		Rodriguez, et al., "Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for Prostate-specific Antigen-positive Prostate Cancer Cells", Cancer Research, Vol. 57, pages 2559-2563, July 1, 1997.	
		Martzuza, "Novel Treatment Approach for Malignant Brain Tumors Developed at Gerogetown", Georgetown University Medical Center, pages 1-8, October 1995.	
		Mineta, et al., "Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas", Nature Medicine, Vol. 1, No. 9, pages 938-943, September 1995.	
		Zhenxiang, et al., "Studies on Viral Immunotherapy of Ascitic Tumors in Mice. I. Results of Treatment on Viruses of Ehrlich and S180 Ascitic Tumor Cells" ACTA Academiae Medicine Sinicae, Vol. 6, No. 3, June 1984.	
		Ganly, et al., "Phase I trial of intratumoral injection with an E1B-attenuated adenovirus, ONYX-015, in patients with recurrent p53(-) head and neck cancer", Proceedings of ASCO, Vol. 16, page 433a, 1997. Abstract 1362.	
		Kirn, et al., "ONYX-015, A selectively replicating adenovirus, has antitumoral activity following IV administration alone and in combination with chemotherapy", Proceedings of ASCO, Vol. 16, page 433a, 1997. Abstract 1564.	
		Izbicka, et al., "Effects of ONYX adenovirus preparations on human tumor colony forming units", Proceedings of ASCO, Vol. 16, page 433a, 1997. Abstract 1554.	
RZ		Kirn, et al., "ONYX-015 selectively replicates in and lyses cells lacking functional p53", Proceedings for the American Association for Cancer Research, Vol. 37, page 352, March 1996. Abstract 2400.	

Examiner Signature

Date Considered

5/17/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 10

Complete if Known

Application Number	09/664,444
Filing Date	September 18, 2000
First Named Inventor	John C. Bell
Group Art Unit	1645
Examiner Name	Robert A. Zeman
Attorney Docket Number	18003

NON PATENT PUBLICATIONS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
RZ		Field, et al., "The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice", J. Hyg., Camb., Vol. 81, pages 267-277, 1978.	
		Spriggs, et al., "Attenuated reovirus type 3 strains generated by selection of haemagglutinin antigenic variants", Nature, Vol. 297, pages 68-70, May 6, 1982.	
		Goldstein, et al., "Factor(s) Presented in Herpes Simplex Virus Type 1-Infected Cells Can Compensate for the Loss of the Large Subunit of the Viral Ribonucleotide Reductase: Characterization of an ICP6 Deletion Mutant", Virology, Vol. 166, pages 41-51, 1988.	
		Perkus, et al., "Deletion of 55 Open Reading Frames from the Termini of Vaccinia Virus", Virology, Vol. 180, pages 406-410, 1991.	
		Meignier, et al., "In Vivo Behavior of Genetically Engineered Herpes Simplex Viruses R7017 and R7020. II. Studies in Immunocompetent and Immunosuppressed Owl Monkeys (Aotus trivirgatus)", The Journal of Infectious Disease, Vol. 162, pages 313-312, 1990.	
		Hughes, et al., "Vaccinia Virus Encodes an Active Thymidylate Kinase that Complements a cdc8 Mutant of Saccharomyces cerevisiae", Journal of Biological Chemistry, Vol. 266, No. 30, pages 20103-20109, October 25, 1991.	
		Kerr, et al. "Vaccinia DNA ligase complements Saccharomyces cerevisiae cdc9, localizes in cytoplasmic factories and affects virulence and virus sensitivity to DNA damaging agents", The EMBO Journal, Vol. 10, No. 13, pages 4343-4350, 1991.	
		Clark, et al. "Protective Effect of WC3 Vaccine Against Rotavirus Diarrhea in Infants During a Predominantly Serotype 1 Rotavirus Season", Journal of Infectious Diseases, Vol. 158, No. 3, pages 570-587, September 1988.	
		Takafuji, et al., "Simultaneous Administration of Live, Enteric-Coated Adenovirus Types 4, 7, and 21 Vaccines: Safety and Immunogenicity", Journal of Infectious Diseases, Vol. 140, No. 1, pages 48-53, July 1979.	
		Taylor, et al., "Virus-Induced Regression of Tumor Growth", Journal of the National Cancer Institute, Vol. 44, pages 515-519, March 1970.	
RZ		Beattie, et al., "Host-Range Restriction of Vaccinia Virus E3L-Specific Deletion Mutants", Virus Genes, Vol. 12, No. 1, pages 89-94, 1996.	

Examiner Signature


Date Considered

5/17/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

7

of 10

Complete if Known

Application Number	09/664,444
Filing Date	September 18, 2000
First Named Inventor	John C. Bell
Group Art Unit	1645
Examiner Name	Robert A. Zeman
Attorney Docket Number	18003

NON PATENT PUBLICATIONS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RZ		Howard, et al., "Retrovirus-Mediated Gene Transfer of the Human...Gene: A Therapy for Cancer", Annals New York Academy of Sciences, Duke University Medical Center, pages 167-187.	
		Suskind, et al., US Dept. of Health, Education & Welfare, N.I.H., National Institute of Allergy and Infectious Disease, and N.C.I., Bethesda, MD., "Viral Agents Oncolytic for Human Tumors in Heterologous Host: Oncolytic Effect of Coxsackie B. Viruses, pages 309-318, October 29, 1956.	
		Bluming, et al., "Regression of Burkitt's Lymphoma...Association with Measles Infection" The Lancet, pages 105-106, July 10, 1971.	
		Pasquinucci, et al., "Possible Effect of Measles on Leukemia", The Lancet, page 136, January 16, 1971.	
		Gross, "Measles and Leukaemia", The Lancet, Pages 397-398, February 20, 1971.	
		Shingu, "Therapeutic effects of bovine enterovirus infection on rabbits with experimentally induced adult T cell leukaemia", Journal of General Virology, Vol. 72, pages 2031-2034, 1991.	
		Faaberg, et al., "Strain Variation and Nuclear Association of Newcastle Disease Virus Matrix Protein", Journal of Virology, Vol. 62, No. 2, pages 586-593, February 1988.	
		Holzaepfel, et al., "The Use of APC3 Virus as a Cancericidal Agent", Cancer, Vol. 10, Pages 577-580, May-June 1957.	
		Smith, et al., "Studies on the Use of Viruses in the Treatment of Carcinoma of the Cervix", Cancer, Vol. 9, pages 1211-1218, November -December 1956.	
		Rukavishnikova, et al. "Some Immunological Mechanisms of the Influenza Virus Antitumour Effect", Acta Virol., Vol. 20, pages 387-394, 1976	
RZ		Verma, et al., "Gene therapy-promises, problem and prospects", Nature, Vol. 389, pages 239-242, September 18, 1997.	

Examiner Signature

Date Considered

5/17/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

8 of 10

Complete if Known

Application Number	09/664,444
Filing Date	September 18, 2000
First Named Inventor	John C. Bell
Group Art Unit	1645
Examiner Name	Robert A. Zeman
Attorney Docket Number	18003

NON PATENT PUBLICATIONS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Kalvakolanu, et al., "Differentiation-dependent activation of interferon-stimulated gene factors and transcription factor NF- κ B in mouse embryonal carcinoma cells", Proc. Natl. Acad. Sci. USA, Vol. 90, pages 3167-3171, April 1993.	
		Foy, et al., "In Vivo CD40-gp39 Interactions are Essential for Thymus-Dependent Humoral Immunity. II. Prolonged Suppression of the Humoral Immune Response by an Antibody to the Ligand for CD40-gp39", J. Exp. Med., Vol. 178, pages 1567-1575, November 1993.	
		Blaese, et al., "In situ Delivery of Suicide Genes for Cancer Treatment", European Journal of Cancer, Vol. 30A, No. 8, Pages 1190-1193, 1994.	
		Zhang, et al., "Gene Therapy with an adeno-associated virus carrying an Interferon gene results in tumor growth suppression and regression", Cancer Gene Therapy, Vol. 3, No. 1, pages 31-38, 1996.	
		Peplinski, et al., "Prevention of Murine Breast Cancer by Vaccination with Tumor Cells Modified by Cytokine-Producing Recombinant Vaccinia Viruses", Annals of Surgical Oncology, Vol. 3, No. 1, pages 15-23.	
		Cotran, et al., "Kinetics of Tumor Cell Growth", Robbins Pathologic Basis of Disease, 4th Edition, page 251.	
		Schloer, et al., "Relationship of Plaque Size and Virulence for Chickens for 14 Representative Newcastle Disease Virus Strains", Journal of Virology, Vol. 2, No. 1, Pages 40-47, January 1968.	
		Tait, et al., "A Phase I Trial of Retroviral BRCA1sv Gene Therapy in Ovarian Cancer", Clinical Cancer Research, Vol. 3, pages 1959-1968, November 1997.	
		Martuza, et al., "Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant", Science, Vol. 252, pages 854-855, May 10, 1991.	
		Hanson, et al., "Identification of Vaccine Strains of Newcastle Disease Virus", Science, Vol. 122, pages 156-157, July 22, 1955.	
		Chambers, et al., "Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma", Proc. Natl. Acad. Sci. USA, Vol. 92, pages 1411-1415, February 1995.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

9 of 10

Complete If Known

Application Number	09/664,444
Filing Date	September 18, 2000
First Named Inventor	John C. Bell
Group Art Unit	1645
Examiner Name	Robert A. Zeman
Attorney Docket Number	18003

NON PATENT PUBLICATIONS

Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue numbers, publisher city and/or country where published	T ²
R2		Asada, "Treatment of Human Cancer with Mumps Virus", Cancer, Vol. 34, pages 1907-1928, December 1974.	
		Sreevalsan, "Chapter 14 Biologic Therapy with Interferon-x and B: Preclinical Studies", Biologic Therapy of Cancer: Principles and Practice, pages 347-364.	
		Stoner, et al., "Effect of Neuraminidase Pretreatment on the Susceptibility of Normal and Transformed Mammalian Cells to Bovine Enterovirus 261", Nature, Vol. 245, pages 319-320, October 12, 1973.	
		Joklik, "Interferons", Chapter 16, Second Edition, pages 382-410, 1990.	
		Schnell, et al., "Construction of a Novel Virus that Targets HIV-1 Infected Cells and Controls HIV-1 Infection", Cell, Vol. 90, pages 849-857, September 5, 1997.	
		Kirchner, et al., "Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines", World J. Urol., Vol. 13, pages 171-173, 1995.	
		Murphy, et al., "Virus Taxonomy", Virology, Second Edition, Chapter 2, pages 9-35, 1990.	
		Csataly, "Viruses in the Treatment of Cancer", The Lancet, page 825, October 9, 1971.	
		Hashiro, et al., "The Preferential Cytotoxicity of Reovirus for Certain Transformed Cell Lines", Archives of Virology, Vol. 54, pages 307-315, 1977.	
		Zhang, "Attenuated newcastle disease virus for induction of interferons to combat neoplasm or viral disease, Database Caplus, on STN Columbus (OH): Chemical Abstract Service, DN 116: 104333, CN 1054192A, Abstract, April 9, 1991.	
→		Gresser, et al., "Exogenous Interferon and Inducers of Interferon in the Treatment of Balb/c Mice inoculated with RC19 Tumor Cells", Nature, Vol. 223, pages 844-845, August 1969.	
R2			

Examiner
Signature


Date
Considered

5/17/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/664,444
(use as many sheets as necessary)		Filing Date	September 18, 2000
		First Named Inventor	John C. Bell
		Group Art Unit	1645
		Examiner Name	Robert A. Zeman
Sheet	10	of	10
		Attorney Docket Number	18003

NON PATENT PUBLICATIONS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>RZ</i>		Csatary, et al., "Virus Vaccines for the Treatment of Cancer", Orvosi Hetilap, Vol. 131, pages 2585-2588, 1990.	
<i>RZ</i>		Eck, et al., "Gene-Based Therapy", Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, Chapter 5, 1996.	

Examiner Signature		Date Considered	5/17/04
-----------------------	---	--------------------	---------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). **2** Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.